Muvalaplin shows promise in lowering Lp(a) levels in clinical trial

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the American Heart Association’s Scientific Sessions 2024.

Fitbit Study Reveals Sleep Duration, Quality, and Consistency Linked to Wide Range of Health Outcomes

What You Should Know: – A groundbreaking new study published in Nature Medicine has unveiled the profound impact of sleep duration, quality, and consistency on

July 29, 2024

Lilly picks a Foghorn target; Mineralys’ $120M PIPE; Sana’s $165M offering

Plus, news about Telix, QSAM Biosciences, Nicox, and Kowa: Eli Lilly selects Foghorn candidate for development: Foghorn’s stock $FHTX jumped 16% on Thursday morning after

February 9, 2024

Théa won’t buy ProQR’s ophthalmic assets; Immunovant’s $130M offering; Inozyme to start pivotal study in October

ProQR’s failed divestiture: Laboratoires Théa scrapped plans to buy ProQR Therapeutics’ late-stage ophthalmic pipeline after announcing a deal in early August for €147.5 million, or

September 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.